Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PRRT with 90Y-DOTATOC in pancreatic neuroendocrine tumors
2018-003768-30Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- May 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 edotreotide in islet cell tumor and neuroendocrine carcinoma (NEC), sponsored by European Institute of Oncology. Primary endpoints: Objective response rate and Feasibility of pancreatic surgery. Started May 2021; status: terminated.
02
Drugs
yttrium-90 edotreotide
03
Conditions
islet cell tumorneuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2018-003768-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003768-30.